Standout Papers

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune ev... 1999 2026 2008 2017 3.9k
  1. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (2002)
    Haidong Dong, Scott E. Strome et al. Nature Medicine
  2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology
  3. Molecular mechanisms of T cell co-stimulation and co-inhibition (2013)
    Lieping Chen, Dallas B. Flies Nature reviews. Immunology
  4. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion (1999)
    Haidong Dong, Gefeng Zhu et al. Nature Medicine
  5. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy (2014)
    Janis M. Taube, Alison Klein et al. Clinical Cancer Research
  6. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations (2016)
    Weiping Zou, Jedd D. Wolchok et al. Science Translational Medicine
  7. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012)
    Janis M. Taube, Robert A. Anders et al. Science Translational Medicine
  8. Inhibitory B7-family molecules in the tumour microenvironment (2008)
    Weiping Zou, Lieping Chen Nature reviews. Immunology
  9. Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future (2015)
    Lieping Chen, Xue Han Journal of Clinical Investigation
  10. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization (2018)
    Miguel F. Sanmamed, Lieping Chen Cell
  11. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity (2004)
    Lieping Chen Nature reviews. Immunology
  12. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 (1992)
    Lieping Chen, William Brady et al. Cell
  13. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production (2001)
    Andrei I. Chapoval, Jian Ni et al. Nature Immunology
  14. Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity (2005)
    Fumiya Hirano, Katsumi Kaneko et al. Cancer Research
  15. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors (1997)
    Ignacio Melero, Walter W. Shuford et al. Nature Medicine
  16. Programmed death ligand-1 expression in non-small cell lung cancer (2013)
    Vamsidhar Velcheti, Kurt A. Schalper et al. Laboratory Investigation
  17. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target (2004)
    R. Houston Thompson, Michael D. Gillett et al. Proceedings of the National Academy of Sciences
  18. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma (2013)
    Sofía Lyford-Pike, Shiwen Peng et al. Cancer Research
  19. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma (2006)
    Ilona Kryczek, Linhua Zou et al. The Journal of Experimental Medicine
  20. B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity (2003)
    Gabriel Sica, In-Hak Choi et al. Immunity
  21. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells (2010)
    Kim L. Good‐Jacobson, Lieping Chen et al. Nature Immunology
  22. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy (2019)
    Jun Wang, Jingwei Sun et al. Nature Medicine
  23. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes (2019)
    Deborah B. Doroshow, Miguel F. Sanmamed et al. Clinical Cancer Research
  24. Resistance Mechanisms to Anti-PD Cancer Immunotherapy (2022)
    Matthew D. Vesely, Tianxiang Zhang et al. Annual Review of Immunology
  25. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities (2022)
    Tae Kon Kim, Esten N. Vandsemb et al. Nature Reviews Drug Discovery
  26. Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach (2025)
    María Villalba, Miguel F. Sanmamed et al. Nature Reviews Clinical Oncology

Immediate Impact

61 by Nobel laureates 42 from Science/Nature 232 standout
Sub-graph 1 of 16

Citing Papers

SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity
2023 StandoutNature
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
5 intermediate papers

Works of Lieping Chen being referenced

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
2014 Standout
and 5 more

Author Peers

Author Last Decade Papers Cites
Lieping Chen 35531 33760 9061 366 54.6k
Suzanne L. Topalian 26635 32079 12249 211 48.3k
James P. Allison 49382 38454 12845 480 70.9k
Jedd D. Wolchok 29224 44357 15851 558 63.2k
F. Stephen Hodi 16392 33441 10242 509 42.8k
Arlene H. Sharpe 47078 28206 16005 406 74.3k
Jérôme Galon 18640 22017 11031 239 38.7k
Wolf H. Fridman 30637 27029 16241 524 56.0k
Dmitry I. Gabrilovich 40807 25340 15291 261 55.9k
Mark J. Smyth 52200 36937 19880 592 80.1k
Gordon J. Freeman 53470 37868 14403 418 81.0k

All Works

Loading papers...

Rankless by CCL
2026